UPDATE : Monday, November 18, 2019
상단여백
Will Biogen be 1st to get FDA nod for Alzheimer’s drug?
Biogen recently unveiled the new results of studies on aducanumab, an inves...
by Kim Yun-mi  |  2019-11-14 11:23
라인
How can Korean drugmakers enter Europe successfully?
Officials from the Korea Pharmaceutical and Bio-Pharma Manufacturers Associ...
by Jeong Sae-im  |  2019-11-13 15:22
라인
Samsung Bioepis expects ₩1 trillion biosimilar sales this year
Samsung Bioepis said it was confident of achieving 1 trillion won ($855.8 m...
by Jeong Sae-im  |  2019-11-13 15:21
라인
[News Focus] ‘FDA could allow resumption of Invossa trial’
Amid the prosecution’s probe into Kolon Life Science’s osteoarthritis gene ...
by Jeong Sae-im  |  2019-11-12 15:48
라인
Celltrion marks robust Q3 sales
Celltrion said that it has recorded sales of 289.1 billion won ($249 millio...
by Lee Han-soo  |  2019-11-07 14:03
라인
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates
Samsung Bioepis said the company would strengthen its partnership with Biog...
by Lee Han-soo  |  2019-11-07 11:16
라인
Court rejects arrest warrant for 2 Kolon execs
A local court has refused to issue an arrest warrant against two executives...
by Jeong Sae-im  |  2019-11-05 13:54
라인
Samsung BioLogics to make Ichnos Sciences’ atopic dermatitis treatment
Samsung Biologics said that it has signed a contract with Ichnos Sciences t...
by Lee Han-soo  |  2019-11-05 12:47
라인
Prosecutors seek to arrest 2 Kolon execs for false Invossa data
Prosecutors have sought arrest warrant for two executives of Kolon Life Sci...
by Jeong Sae-im  |  2019-10-31 15:34
라인
Syntekabio passes prior review for Kosdaq listing
Syntekabio, a new drug developer using artificial intelligence (AI)-based g...
by Jeong Sae-im  |  2019-10-31 13:27
라인
Prosecution seeks jail term for Samsung execs for destroying evidence
Prosecutors demanded jail terms of one to four years for Samsung executives...
by Jeong Sae-im  |  2019-10-29 13:10
라인
KangStem Biotech changes strategy for atopic dermatitis drug
KangStem Biotech changed its strategy for Furestem-AD, an investigational s...
by Jeong Sae-im  |  2019-10-28 15:34
라인
Bridge Biotherapeutics passes preliminary review for Kosdaq listing
Bridge Biotherapeutics has passed the regulatory agency’s preliminary revie...
by Jeong Sae-im  |  2019-10-25 15:05
라인
Celltrion launches Herzuma in Brazil
Celltrion Healthcare said that it has launched its anticancer antibody bios...
by Lee Han-soo  |  2019-10-25 13:56
라인
KangStem Biotech fails in phase-3 study on atopic dermatitis drug
KangStem Biotech said it has failed to prove the efficacy of Furestem-AD, a...
by Jeong Sae-im  |  2019-10-25 11:17
라인
Samsung Bioepis' biosimilar sales in EU top $180 million in Q3
Samsung Bioepis' biosimilar sales in European Union surpassed $180 mill...
by Lee Han-soo  |  2019-10-23 17:43
라인
Medipost wins patent for mesenchymal stem cell culture in China
Medipost said that it has registered a patent for cultivating mesenchymal s...
by Lee Han-soo  |  2019-10-23 16:30
라인
Celltrion unveils clinical results of Remsima SC in treating IBD
Celltrion said that is has presented the phase 1, part 2 trial results for ...
by Lee Han-soo  |  2019-10-22 17:00
라인
Biogen, Samsung Bioepis to present biosimilar data at EU conference
Biogen and Samsung Bioepis said that they plan to present new real-world da...
by Lee Han-soo  |  2019-10-22 11:31
라인
Medytox exported ₩3.3 billion worth of unqualified BTX
The Ministry of Food and Drug Safety ordered Medytox to recall and discard ...
by Jeong Sae-im  |  2019-10-18 16:02
여백
여백
여백
Back to Top